Skip to content

A multicenter randomized controlled trial of functional dyspepsia treated with acupuncture related to meridians and viscera

A multicenter randomized controlled trial of functional dyspepsia treated with acupuncture related to meridians and viscera

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000510
Enrollment
Unknown
Registered
2024-10-01
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia

Interventions

Sham acupuncture plus placebo group:12 sessions of sham acupuncture treatment (non-acupoints, shallow puncture, three times a week for four weeks) and itopride placebo tablets for 20 days (50 mg of it
Acupuncture plus itopride placebo Group:12 sessions of verum acupuncture treatment (real acupoints manual acupuncture three times a week for four weeks) and itopride placebo tablets for 20 days (50 mg
Itopride plus sham acupuncture group :Itopride tablets for 20 days (50 mg of itopride orally 3 times a day, 5 days per week, for 4 weeks) and 12 sessions of sham acupuncture treatment (non-acupoints,

Sponsors

The Hunan University of Chinese Medicine/The Second Affiliated Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (i)Aged 18-60 years and long-term residents of Changsha. (ii)Diagnosed with FD-PDS according to the Rome IV criteria. (iii)No structural abnormalities were detected through upper gastrointestinal endoscopy surveillance. (iv)Non-refractory FD. (v)Patients who are helicobacter pylori-negative or have persistent symptoms after helicobacter pylori eradication for one month. (vi)Good compliance.

Exclusion criteria

Exclusion criteria: (i)Use drugs such as prokinetics acid suppression mucosal protectants or other FD-related agents within 2 weeks. (ii)Do not tolerate acupuncture. (iii)Receive acupuncture treatment within 2 weeks. (iv)Have gastrointestinal diseases other than PDS. (v)Pregnant or lactating women and those attempting conception. (vi)Patients who are participating in other clinical trials. (vii)Diagnosed with malignancy or other serious conditions such as severe heart liver lung or kidney dysfunction severe autoimmune disease or endocrine diseases. (viii)Unable to effectively communicate for any reason such as severe mental illness cognitive impairment or impaired language comprehension.

Design outcomes

Primary

MeasureTime frame
The proportion of responder ;The elimination rate;

Secondary

MeasureTime frame
The Chinese version of Short Form-Nepean Dyspepsia Life Quality Index;The Chinese version of the Hospital Anxiety and Depression Scale;advers effects;Acupuncture expectation;The Chinese version of the Nepean Dyspepsia Symptom Index;

Countries

China

Contacts

Public ContactWeiai Liu/Mi Liu

The Second Affiliated Hospital of Hunan University of Chinese Medicine/Hu'nan University of Chinese Medicine

55999630@qq.com+8613787016026/+86 151 1638 7811

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026